ReviewAmerican journal of hypertension2020
Chemerin as a Driver of Hypertension: A Consideration.
Review in American journal of hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Raised levels of chemerin in women with preeclampsia: A meta-analysis.Biomolecules & biomedicine · 2024Pooled it
- Trial
- Trial
- Chemerin Normal Function and Roles in Metabolic and Nonmetabolic Disorders: An Up-To-Date Comprehensive Review.Biochemistry research international · 2026Review
- Chemerin/ChemerinR1 axis and inflammation-related diseases.Frontiers in molecular biosciences · 2026Review
- Chemerin and Asprosin as Promising Biomarkers of Metabolic Syndrome: A Scoping Review.Current obesity reports · 2025Article
- Editorial for the Special Issue: Recent Advances in Adipokines-2nd Edition.Biomedicines · 2025Article
- Chemerin as a Driver of Cardiovascular Diseases: New Perspectives and Future Directions.Biomedicines · 2025Review
- Vascular effects of perivascular adipose tissue-derived chemerin in obesity-associated cardiovascular disease.Cardiovascular diabetology · 2025Review
- Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma.Biomedicines · 2025Article
- Assessing personalized molecular portraits underlying endothelial-to-mesenchymal transition within pulmonary arterial hypertension.Molecular medicine (Cambridge, Mass.) · 2024Article
- Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives.Journal of clinical medicine · 2024Review
- Chemerin in the Spotlight: Revealing Its Multifaceted Role in Acute Myocardial Infarction.Biomedicines · 2024Review
- Chemerin Levels in COVID-19 Are More Affected by Underlying Diseases than by the Virus Infection Itself.Biomedicines · 2024Article
- Article
- The Interplay of Lifestyle and Adipokines in the Non-Obese Stroke-Prone Spontaneously Hypertensive Rats.Antioxidants (Basel, Switzerland) · 2023Article
- Chemerin is resident to vascular tunicas and contributes to vascular tone.American journal of physiology. Heart and circulatory physiology · 2023Article
- Review
- Chemerin as an Inducer of β Cell Proliferation Mediates Mitochondrial Homeostasis and Promotes β Cell Mass Expansion.International journal of molecular sciences · 2023Article
- Third-Trimester Maternal Serum Chemerin and Hypertension After Preeclampsia: A Prospective Cohort Study.Journal of the American Heart Association · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
The protein chemerin (tazarotene-induced gene, TIG2; RARRES2) is a relatively new adipokine. Many studies support that circulating chemerin levels associate strongly and positively with body mass index, visceral fat, and blood pressure. Here, we focus on the specific relationship of chemerin and blood pressure with the goal of understanding whether and how chemerin drives (pathological) changes in blood pressure such that it could be interfered with therapeutically. We dissect the biosynthesis of chemerin and how current antihypertensive medications change chemerin metabolism. This is followed with a review of what is known about where chemerin is synthesized in the body and what chemerin and its receptors can do to the physiological function of organs important to blood pressure determination (e.g., brain, heart, kidneys, blood vessels, adrenal, and sympathetic nervous system). We synthesize from the literature our best understanding of the mechanisms by which chemerin modifies blood pressure, with knowledge that plasma/serum levels of chemerin may be limited in their pathological relevance. This review reveals several gaps in our knowledge of chemerin biology that could be filled by the collective work of protein chemists, biologists, pharmacologists, and clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.